Synonyms: EXAMPLE 2 [WO2014102818A1] | Oxemia® | ZYAN-1 | ZYAN1
Compound class:
Synthetic organic
Comment: Desidustat (ZYAN1) is an orally bioavailable inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) enzymes (PHD1, PHD2, and PHD3; genes EGLN2, EGLN1 and EGLN3 respectively) [5]. It was developed as a strategy to promote erythropoietin (EPO) synthesis and erythropoiesis by stabilising HIF-α transcription factors, as a mechanism to treat anemia associated with chronic diseases. Orally active HIF-PH inhibitors are being exploited as alternatives to injectable erythropoietin stimulating drugs, such as epoetin and darbepoetin, to treat anemia.
|
|
References |
1. Agrawal D, Varade D, Shah H, Nazar A, Krishnan J, Shukla V, Ramakrishna C, Bandara Galahitiyawa MC, Mavani SB, Rajanna S et al.. (2022)
Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND). Am J Nephrol, 53 (5): 352-360. [PMID:35462372] |
2. Desai RC, Pandaya V, Patel PR. (2014)
Novel quinolone derivatives. Patent number: WO2014102818A1. Assignee: Cadila Healthcare Limited. Priority date: 24/12/2012. Publication date: 03/07/2014. |
3. Dhillon S. (2022)
Desidustat: First Approval. Drugs, 82 (11): 1207-1212. [PMID:35834123] |
4. Gang S, Khetan P, Varade D, Chinta VR, Mavani S, Gupta U, Reddy SVK, Rajanna S, Jeloka T, Ruhela V et al.. (2022)
Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D). Am J Nephrol, 53 (5): 343-351. [PMID:35462369] |
5. Patel H, Joharapurkar AA, Pandya VB, Patel VJ, Kshirsagar SG, Patel P, Gevriya B, Jain MR, Srinivas NR, Patel PR et al.. (2018)
Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia. Xenobiotica, 48 (1): 37-44. [PMID:28042744] |